Celadon is this morning delighted to announce its admission to the London Stock Exchange AIM market, raising £8.5m and bringing the total raise in the past year to ~£20m.
Our goal is to become the provider and partner of choice for researching and producing pharmaceutical-grade cannabinoid-based medicines. We have built an integrated supply chain and have received the relevant licencing from the UK governance to cultivate high-THC medical cannabis in our 100,000 sq ft UK facility, including a UK GMP-designed laboratory.
With an MHRA conditionally approved trial for cannabinoid-based medicinal products for chronic pain, we have ambitious plans for Celadon Pharmaceuticals Plc.
Recent Comments